A phase II study of dacarbazine, cisplatin, interferon-α and high-dose interleukin-2 in 'poor-risk' metastatic melanoma

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1530-1533

  Proebstle, T M ^a   Scheibenbogen, C ^b   Sterry, W ^c   Keilholz, U ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Brain metastases; Chemo immunotherapy; Interleukin 2; Melanoma; Ocular melanoma

Indexed keywords

ALPHA2A INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2;

ADVANCED CANCER; ANEMIA; ARTICLE; BRAIN METASTASIS; DIARRHEA; EYE MELANOMA; HYPOTENSION; LEUKOPENIA; LIVER TOXICITY; MELANOMA; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; SKIN DISEASE; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

EID: 0030217981     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00135-9     Document Type: Article

References (14)

1. 1. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with IL-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989, 7, 1863-1874.
2. 2. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 10, 1338-1343.
3. 3. Legha S, Buzaid AC. Role of recombinant IL-2 in combination with interferon-alpha and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993, 6 (Suppl 9), 27-32.
4. 4. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993, 11, 2173-2180.
5. 5. Atkins MB, O'Boyle KR, Sosman JA, et al. Multiinstitutional phase II trial of intensive combination chemotherapy for metastatic melanoma. J Clin Oncol 1994, 12, 1553-1560.
6. 6. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989, 7, 486-498.
7. 7. West WH, Tauer KW, Yanelli JR, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987, 316, 898-905.
8. 8. White RL Jr, Schwartzentruber DJ, Guleria A, et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994, 74, 3212-3222.
9. 9. Keilholz U, Scheibenbogen C, Tilgen W, et al. Interferon-alpha and IL-2 in the treatment of metastatic melanoma: comparison of two phase II trials. Cancer 1993, 72, 607-614.
10. 10. Keilholz U, Scheibenbogen C, Möhler T, et al. Addition of dacarbazine or cisplatinum to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects. Mel Res 1995, 5, 283-287.
11. 11. Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Int Med 1987, 107, 293-300.
12. 12. Legha S. Current therapy for malignant melanoma. Semin Oncol 1989, 16, 34-44.
13. 13. Dorval T, Fridmann WH, Mathiot C, Pouillart P. Interleukin-2 therapy for metastic uveal melanoma. Eur J Cancer 1992, 28, 2087.
14. 14. Keilholz U, Scheibenbogen C, Schlag P, et al. Regional adoptive immunotherapy with IL-2 and LAK cells for liver metastases of malignant melanoma. Eur J Cancer 1994, 30, 103-105.